Based on a licence from Else Marit Inderberg and Sebastien Wälchli’s group at The Section of Cell Therapy at Oslo University Hospital, the company Zelluna Immunotherapy is developing natural killer cells that are steered by T cell receptors. The aim is to offer different forms of targeted immunotherapy treatments that do not have to be individually tailored for each patient. Zelluna Immunotherapy receives NOK 83 million from investors and the Research Council of Norway to continue its work on this new form of cancer immunotherapy.
Published in major journals, first or last author from Oslo University Hospital.
In Well-Treated Celiac Patients Low-Level Mucosal Inflammation Predicts Response to 14-day Gluten Challenge
Adv Sci (Weinh), 8 (4), 2003526
A heterozygous germline CD100 mutation in a family with primary sclerosing cholangitis
Sci Transl Med, 13 (582)
Patient-tailored design for selective co-inhibition of leukemic cell subpopulations
Sci Adv, 7 (8)